Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neda Nikbakht

Showing results (81-90 of 88) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 88 results.
The British Journal of Dermatology|May 29, 2025
Efficacy and Safety of Rigosertib in Patients with Recessive Dystrophic Epidermolysis Bullosa Associated Advanced/Metastatic Cutaneous Squamous Cell CarcinomaMartin Laimer, Andrew P South, Elisabeth Mayr, et al.
Blood Advances|June 17, 2024
Safety and feasibility of third-party cytotoxic T lymphocytes for high-risk patients with COVID-19Dolores Grosso, John L Wagner, Allyson O'Connor, et al.
Blood Advances|March 29, 2023
Preclinical evaluation of anti-CD38 therapy in mature T-cell neoplasmsColleen Isabelle, William T Johnson, Kathleen McConnell, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 20, 2019
Inherited Interleukin 2-Inducible T-Cell (ITK) Kinase Deficiency in Siblings With Epidermodysplasia Verruciformis and Hodgkin LymphomaLeila Youssefian, Hassan Vahidnezhad, Mehdi Yousefi, et al.
Cancer Discovery|March 3, 2018
<i>In Vivo</i> E2F Reporting Reveals Efficacious Schedules of MEK1/2-CDK4/6 Targeting and mTOR-S6 Resistance MechanismsJessica L F Teh, Phil F Cheng, Timothy J Purwin, et al.
Cancer Discovery|December 5, 2018
Correction: <i>In Vivo</i> E2F Reporting Reveals Efficacious Schedules of MEK1/2-CDK4/6 Targeting and mTOR-S6 Resistance MechanismsJessica L F Teh, Phil F Cheng, Timothy J Purwin, et al.
JAMA Dermatology|July 20, 2022
Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides): The FLASH Phase 3 Randomized Clinical TrialEllen J Kim, Aaron R Mangold, Jennifer A DeSimone, et al.
Science Immunology|February 27, 2026
Human LFA-1 governs T cell immune surveillance of the skinAhmad Yatim, Leila Youssefian, Aida Idani, et al.
Pageof 9

Showing results (81-90 of 88) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 88 results.
The British Journal of Dermatology|May 29, 2025
Efficacy and Safety of Rigosertib in Patients with Recessive Dystrophic Epidermolysis Bullosa Associated Advanced/Metastatic Cutaneous Squamous Cell CarcinomaMartin Laimer, Andrew P South, Elisabeth Mayr, et al.
Blood Advances|June 17, 2024
Safety and feasibility of third-party cytotoxic T lymphocytes for high-risk patients with COVID-19Dolores Grosso, John L Wagner, Allyson O'Connor, et al.
Blood Advances|March 29, 2023
Preclinical evaluation of anti-CD38 therapy in mature T-cell neoplasmsColleen Isabelle, William T Johnson, Kathleen McConnell, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 20, 2019
Inherited Interleukin 2-Inducible T-Cell (ITK) Kinase Deficiency in Siblings With Epidermodysplasia Verruciformis and Hodgkin LymphomaLeila Youssefian, Hassan Vahidnezhad, Mehdi Yousefi, et al.
Cancer Discovery|March 3, 2018
<i>In Vivo</i> E2F Reporting Reveals Efficacious Schedules of MEK1/2-CDK4/6 Targeting and mTOR-S6 Resistance MechanismsJessica L F Teh, Phil F Cheng, Timothy J Purwin, et al.
Cancer Discovery|December 5, 2018
Correction: <i>In Vivo</i> E2F Reporting Reveals Efficacious Schedules of MEK1/2-CDK4/6 Targeting and mTOR-S6 Resistance MechanismsJessica L F Teh, Phil F Cheng, Timothy J Purwin, et al.
JAMA Dermatology|July 20, 2022
Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides): The FLASH Phase 3 Randomized Clinical TrialEllen J Kim, Aaron R Mangold, Jennifer A DeSimone, et al.
Science Immunology|February 27, 2026
Human LFA-1 governs T cell immune surveillance of the skinAhmad Yatim, Leila Youssefian, Aida Idani, et al.
Pageof 9